02172 MICROPORT NEURO
- 9.090
- -0.060-0.66%
MICROPORT NEURO News
Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
Microport NeuroTech Swings to Profit in 2023 as Revenue Jumps 22%
Microport NeuroTech (HKG:2172) recorded an attributable profit of 145.5 million yuan in 2023, versus an attributable loss of 21.8 million yuan in 2022, according to the company's annual report filed w
微創腦科學：2023年度報告
Minimally Invasive Brain Science (02172.HK): Steady improvement in performance, consolidation of leading position in domestic production of neurological intervention
Event: Minimally Invasive Brain Science announced its 2023 annual results. In 2023, the company achieved operating income of 666 million yuan (+21.6%), net profit of 135 million yuan, and adjusted net profit of 195 million yuan (49.
Minimally Invasive Brain Science (2172.HK): Benefiting from steady revenue growth and reduced expense ratios, net profit is expected to achieve high growth in 2024
The company's revenue in 2023 was +22% year-on-year to RMB 670 million, slightly lower than market expectations. However, benefiting from a marked improvement in gross margin and a decrease in the cost ratio during the period, adjusted net profit recorded a strong 50% year-on-year increase. For the recent market
Minimally Invasive Brain Science (02172.HK): Adjusted profit exceeds expectations, focusing on new domestic products and overseas sales
The adjusted net profit for 2023 exceeded our expectations. The company announced its 2023 results: revenue of 666 million yuan, +22% year over year; adjusted net profit of 195 million yuan, +50% year over year. Due to the 2H23 industry rectification
The results for the full year of 2023 were announced. What was the performance of innovative medical device companies under the collection test?
Hengqiang, the strongest in innovative medical devices
Minimally Invasive Brain Science (02172.HK): High profit growth can be expected to accelerate in 2024
Investment Highlights The company announced its 2023 results, with revenue of 666 million yuan in 2023, an increase of 21.6% over the previous year, and net profit of 135 million yuan. It turned a loss into profit and achieved strong growth over the previous year. We believe that with the company
Minimally Invasive Brain Science (02172.HK): Steady Improvement in Performance, Continued Outstanding Performance of Core Products*Luo Jiarong* Announcement Comment
The company's performance has been improving steadily. The company announced its 23-year results, achieving revenue of 666 million yuan (YOY +21.6%); adjusted net profit of 195 million yuan (YOY +49.5%); and net profit of 1.35 million yuan
MICROPORT NEURO To Go Ex-Dividend On June 28th, 2024 With 0.11 HKD Dividend Per Share
March 30th - $MICROPORT NEURO(02172.HK)$ is trading ex-dividend on June 28th, 2024. Shareholders of record on July 2nd, 2024 will receive 0.11 HKD dividend per share on August 22nd, 2024. The ex-d
Minimally Invasive Brain Science (02172) grants 2.191 million share options
Minimally Invasive Brain Science (02172) issued an announcement. On March 28, 2024, the company decided to comply with the company's 20...
Minimally Invasive Brain Science (02172.HK) suggests changing the English name to “MicroPort NeuroScientific Corporation”
GLONGHUI March 27 | Minimally Invasive Brain Science (02172.HK) issued an announcement. The company's board of directors proposed changing the company's English name from “MicroPort NeuroTech Limited” to “MicroPort NeuroScientific Corporation”. The company's Chinese name remains unchanged.
Minimally Invasive Brain Science (02172) will pay a final dividend of HK$0.11 per share on August 22
Minimally Invasive Brain Science (02172) issued an announcement which will be distributed on August 22, 2024 until December 2023...
Minimally Invasive Brain Science (02172) announced annual results, profit attributable to shareholders of 146 million yuan, and turned a year-on-year loss into a profit
According to Zhitong Finance App News, Minimally Invasive Brain Science (02172) announced its annual results for the year ended December 31, 2023. The group achieved revenue of 666 million yuan (RMB, same below), an increase of 21.61% over the same period last year; profit attributable to shareholders was 146 million yuan, and losses due to shareholders were 21.755 million yuan during the same period last year, turning a loss into profit from the previous year; basic profit of 0.25 yuan per share; it is proposed to distribute a final dividend of HK$0.11 per share. According to the announcement, the increase in revenue was mainly due to a variety of market-leading products (including Tubridge blood flow guided dense mesh stents and Bridge vertebral artery
MICROPORT NEURO: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Minimally Invasive Brain Science (02172.HK) plans to hold a board meeting on March 27 to approve annual results
Gelonghui, March 15, 丨 Minimally Invasive Brain Science (02172.HK) announced that the company would like to hold a board meeting on March 27, 2024 (Wednesday) to consider and approve the Group's annual results and announcements for the year ended 31 December 2023, and to consider the payment of a final dividend (if any), and to deal with other matters.
MICROPORT NEURO: DATE OF BOARD MEETING
Financial Services Association Venture Capital Connect: In February, the domestic medical sector raised 4.1 billion yuan, down 42% month-on-month, with the highest amount of financing for innovative drugs
In February 2024, there were 80 private equity financing incidents in the domestic healthcare sector, a decrease of 27% from the previous month; the total amount of disclosed financing was about 4,066 billion yuan, a decrease of 42% from the previous month.
Changes in Hong Kong stocks | Minimally Invasive Brain Science (02172) rose more than 5%, leading medical device stock institutions optimistic about the future prospects of overseas expansion of domestic medical devices
The increase in medical device stocks increased in the afternoon. As of press release, Minimally Invasive Brain Science (02172) rose 6.46% to HK$9.4; Chunli Healthcare (01858) rose 4.61% to HK$9.31; Haohai Biotech (06826) rose 3.71% to HK$34.95; and Novi Health (06606) rose 2.35% to HK$18.28.
Highlights of the morning brokerage meeting: Focus on opportunities to increase the localization rate of medical devices
At today's brokerage morning meeting, CICC believes that it is concerned about opportunities to increase the localization rate of medical devices; CITIC Construction Investment pointed out that the future of the cross-border e-commerce industry has great potential; and Guotai Junan said that it is concerned about undervalued consumption of blue-chip stocks.
Analysis
Price Target
No Data
